Prescribing Haloperidol

Why Haloperidol Still Matters

Haloperidol is the drug every psychiatrist loves to disparage and every hospital keeps in the crash cart. It is out of fashion in outpatient clinics, blamed for a generation of tardive dyskinesia, and reflexively passed over for a newer atypical. Yet it is still one of the most-prescribed antipsychotics in the world, because for certain jobs nothing does them faster, cheaper, or more reliably.

Haloperidol isn't a bad drug; it is a narrow one. Head-to-head, it matches the atypicals for positive symptoms and ranks near the top for acute mania, so efficacy is not its problem. Tolerability is. It buys its potent, clean D2 blockade at the price of extrapyramidal side effects and, over years, tardive dyskinesia. Much of the "atypicals are more effective" literature is an artifact of comparing modern agents against overdosed haloperidol (10–15 mg/day plus anticholinergics), a regimen that produced parkinsonian slowing mistaken for negative symptoms and cognitive dulling mistaken for the drug being dumb. Dosed properly and used for the right patient, haloperidol is a precise instrument.

It earns its keep in acute agitation and psychosis, acute mania, and long-acting injectable maintenance for the cost-constrained patient. A month of haloperidol decanoate costs about $15; a month of an atypical LAI runs $900–1,185. The difference is roughly $12,000 per patient per year, enough to decide whether some patients get a depot at all.

Part 1: Indications

FDA-Approved Uses

• Schizophrenia
• Acute manic episodes in bipolar disorder
• Tics and vocal utterances of Tourette syndrome
• Severe behavioral problems / hyperactivity in children (historical labeling; rarely used this way now)
• Acute agitation associated with psychosis

Haloperidol is also used extensively off-label for delirium and for the behavioral control of agitation in the ED and ICU, though, as below, the delirium evidence is weaker than tradition suggests.

Where Haloperidol Is Strongest

Acute agitation and psychosis, the ED/inpatient mainstay. High potency and rapid onset (meaningful effect in 30–60 minutes for acute symptoms, faster IM) make it the reflexive choice for the acutely agitated psychotic patient. It can be given PO, IM, or IV. The classic "B-52" (haloperidol 5 mg plus lorazepam 2 mg plus diphenhydramine 50 mg) is imperfect but ubiquitous for a reason.

Acute mania, where it ranks among the best. A dose-equivalence network meta-analysis of antipsychotics in acute mania and schizophrenia (42 RCTs, n=11,396; BMJ Ment Health 2023) found that haloperidol's optimal mean dose for mania was 10.1 mg/day, about 8.1% lower than the dose used for schizophrenia (~11.0 mg; p<0.001). That fits the clinical experience that mania responds to somewhat lower antipsychotic doses. It works fast on manic agitation. The catch is that high-potency typicals may worsen or precipitate depression in bipolar patients over the longer term, so haloperidol is a bridge, not a maintenance mood stabilizer.

Schizophrenia: as effective as the atypicals, and cheaper. In fair head-to-head comparisons haloperidol matches atypical antipsychotics for positive symptoms. The CATIE trial made a broader point: mid-potency perphenazine was as effective as the atypicals, and the apparent atypical superiority in older trials evaporated once you stopped dosing haloperidol at 15 mg with a Cogentin chaser.

Tourette syndrome. One of its oldest indications; effective for tic suppression, though the EPS/TD liability means many clinicians now start with alpha-2 agonists or aripiprazole and reserve haloperidol for refractory tics.

Where the Evidence Is Weaker Than Its Reputation

Delirium. This is the drug's most reflexive off-label use, and the evidence does not support routine use. A large NEJM trial (~1,000 ICU patients) of haloperidol 2.5 mg IV TID (± PRN to a max of 20 mg/day) versus placebo found no difference in days alive and out of the hospital, mortality, delirium- or coma-free days, or serious adverse events, and a nonsignificant trend toward more QT prolongation. A 2023 meta-analysis likewise failed to show a benefit in delirium-free days. Haloperidol may still be reasonable to control dangerous agitation within delirium, but it does not treat the delirium itself, and in frail patients it adds QT, hypotension, and hypothermia risk.

Part 2: Workup and Candidacy

Haloperidol needs less lab infrastructure than lithium or clozapine. Do not skip the cardiac screen or the baseline movement exam.

Who Is a Poor Candidate?

• Pre-existing tardive dyskinesia: TD risk with haloperidol is substantially higher than with atypicals; avoid if you have a better option.
• A history of severe EPS/akathisia intolerance: reach for a lower-potency typical or an atypical.
• Baseline QT prolongation or significant cardiac conduction disease: use with caution and monitoring, if at all.
• Elderly patients with dementia-related psychosis: the class-wide boxed warning (increased mortality) applies; use only when agitation is dangerous and alternatives have failed.
• Parkinson's disease / Lewy body dementia: high-potency D2 blockade can be catastrophic; avoid.

Part 3: How to Start and Dose

Formulations

• Oral tablets (0.5, 1, 2, 5, 10, 20 mg) and oral concentrate: for scheduled dosing and titration.
• Haloperidol lactate for injection (IM; IV use is off-label): for acute agitation and delirium; rapid onset.
• Haloperidol decanoate: the long-acting depot, dosed monthly.

Oral / Acute Dosing

• Acute agitation: a typical initial dose is 2–5 mg PO or IM, depending on acuity, body size, and prior exposure; repeat as needed with attention to cumulative dose and QT.
• Schizophrenia / mania maintenance: most patients are well served by 5–15 mg/day. Pushing to 20 mg or beyond by reflex is what gives haloperidol its bad reputation: more D2 blockade above the therapeutic threshold buys mostly EPS, not efficacy.
• Acute mania target: aim for the ~10 mg/day neighborhood shown optimal in meta-analysis, then transition mania patients to a proper mood stabilizer.
• Delirium (agitation rescue): 2.5 mg IV up to TID, max 20 mg/day, tapering off as the patient settles.

Long-Acting Injectable: Haloperidol Decanoate

Haloperidol's economics are most compelling in the depot.

• Conversion from oral to depot: the monthly IM dose is roughly 10–15× the total oral daily dose (a patient stable on 10 mg PO/day → ~100–150 mg decanoate monthly), though the label caps the first injection at 100 mg and gives any balance 3 to 7 days later. This clean multiple is easier to remember than fluphenazine decanoate's ~1.2× oral conversion, which is one reason haloperidol decanoate is the more popular typical LAI.
• Typical maintenance: on the order of 50–200 mg IM every 4 weeks, titrated to response (~200 mg/month is a common upper range).
• Pharmacokinetics: plasma concentration rises gradually and peaks around day 6 after an injection.
• Oral overlap: because the depot rises slowly, standard practice is to continue oral haloperidol for 2–3 weeks after the first injection to prevent relapse (strictly, ~1 week suffices given the day-6 peak, but most clinicians overlap conservatively).
• Cost: ~$15/month for 200 mg decanoate, versus $900–1,185/month for atypical LAIs.

Dose Adjustments and Special Populations

• IV use and QTc: IV haloperidol (off-label, for ICU delirium) carries a specific FDA warning for QT prolongation and torsades. Use continuous cardiac monitoring, correct potassium/magnesium, and avoid in prolonged QT. Oral and IM dosing at usual doses carry much less risk.
• Hepatic impairment: haloperidol is hepatically metabolized (glucuronidation, CYP3A4, CYP2D6); reduce the dose in significant hepatic disease.
• Renal impairment: use caution; haloperidol is not significantly dialyzable. Smoking: CYP1A2 is a minor pathway, but heavy smoking can modestly lower levels.
• Geriatric: start 0.25–0.5 mg; the class boxed warning (dementia mortality) applies and the elderly are especially prone to EPS.
• Pediatric: approved for schizophrenia, Tourette's, and severe behavioral disorders in children, at weight-based low doses.

Stopping and Switching

• Discontinuation: taper to avoid withdrawal dyskinesia and rebound; the decanoate self-tapers over months, so account for the long tail when switching.

Part 4: Monitoring

Haloperidol's monitoring burden is lighter than lithium's, but two things you have to keep tracking: movements and, in at-risk patients, the QT interval.

Routine AIMS screening exists for early detection: the longer TD goes unrecognized and the longer the offending drug continues, the lower the chance of recovery. Catch abnormal movements early and you can act while they are still reversible.

Part 5: Side Effects and How to Manage Them

Haloperidol's problems are overwhelmingly neurological (EPS and TD). They are dose-dependent, and most of the acute ones are preventable or reversible. Its metabolic profile, the thing that plagues the atypicals, is one of its advantages.

Extrapyramidal Symptoms (EPS)

EPS are haloperidol's defining liability. High-potency D2 blockade produces the full spectrum, often early:

• Acute dystonia: sustained muscle contractions (oculogyric crisis, torticollis, laryngospasm), typically in the first hours to days, more common in young men. This is an emergency: benztropine 1–2 mg IM/IV or diphenhydramine 25–50 mg IM/IV relieves it quickly.
• Akathisia: an inner restlessness that patients experience as unbearable; frequently mistaken for worsening agitation (and then, disastrously, treated with more haloperidol). Manage by lowering the dose, adding a beta-blocker (propranolol 10–20 mg TID), or a benzodiazepine; anticholinergics help akathisia less reliably than they help dystonia/parkinsonism.
• Drug-induced parkinsonism: bradykinesia, rigidity, tremor, masked facies. This is the syndrome that masquerades as negative symptoms and cognitive dulling. Manage by lowering the dose or adding an anticholinergic.

Anticholinergic co-treatment. Haloperidol is not intrinsically anticholinergic (unlike low-potency chlorpromazine/thioridazine), so it does not self-protect against EPS the way sedating typicals do. Standard practice is to co-prescribe benztropine (Cogentin) 0.5–2 mg BID/TID or trihexyphenidyl (Artane) 1–2 mg BID/TID, to restore the dopamine-acetylcholine balance in the extrapyramidal circuits, during active therapy and not indefinitely. The anticholinergic has costs of its own: dry mouth, blurred vision, constipation, urinary retention, and confusion (especially in the elderly).

Tardive Dyskinesia (TD)

TD is the reason haloperidol's use has declined. Chronic D2 blockade drives receptor upregulation and supersensitivity, producing involuntary, often irreversible movements, classically orofacial (lip smacking, chewing, tongue protrusion, grimacing), sometimes limb/trunk choreoathetosis.

• Incidence: roughly 5.4% per year in non-elderly adults on haloperidol, versus ~0.8%/year for atypicals, in a review of one-year studies. Cumulatively, older literature reports figures as high as 20–50% of chronic typical-antipsychotic patients over time. Age moves the figure more than anything else: prospective follow-up of older patients on conventional antipsychotics puts cumulative TD near 25% at one year, 34% at two years and 53% at three.
• In the elderly: every agent carries more risk. Atypicals ran about 5.3%/year in patients over 54 in the same review, several times their rate in younger adults, but the first-generation figures above are higher still, and a matched nine-month comparison in older patients found significantly more TD on haloperidol than on risperidone.
• Other risk factors: higher doses, longer exposure, pre-existing movement disorders, anticholinergic co-use, substance use, and postmenopausal status.

Management

1. Prevent. Use the lowest effective dose, reassess the need for the drug at every visit, and prefer lower-potency or atypical agents when TD risk is high.
2. Detect early (routine AIMS): longer exposure means lower recovery odds.
3. Withdraw the offending drug carefully. Do not stop abruptly: abrupt discontinuation can unmask or worsen TD (withdrawal-emergent dyskinesia). Taper slowly.
4. Treat. The evidence-based options are the VMAT2 inhibitors: valbenazine (Ingrezza) and deutetrabenazine (Austedo) are FDA-approved for TD; tetrabenazine is used off-label. (Note: anticholinergics help tardive dystonia but can worsen classic TD; don't reflexively reach for benztropine here.)

Neuroleptic Malignant Syndrome (NMS): Rare but Lethal

A medical emergency, more associated with high-potency agents like haloperidol: hyperthermia, "lead-pipe" rigidity, autonomic instability, and altered mental status, with elevated CK as a supporting laboratory finding. Stop the antipsychotic immediately, provide aggressive supportive care and cooling, and use dantrolene and/or bromocriptine in severe cases. Know the tetrad cold; it can appear at any point in treatment.

Cardiac / QT

• QT prolongation is real but modest: roughly 5 msec at 15 mg/day (less than iloperidone's ~9 msec; more than risperidone's ~3-4 msec). It becomes clinically important with IV administration, high doses, electrolyte derangement, or co-administered QT drugs; IV haloperidol has been associated with torsades, so continuous cardiac monitoring is standard for IV use.
• Sudden cardiac death: antipsychotics as a class, typical and atypical, roughly double the risk, an absolute excess on the order of ~3 deaths per 1,000 patient-years (Ray et al., NEJM 2009), higher with dose, age, and frailty.

Metabolic Profile

Here haloperidol beats the atypicals decisively:

• Weight gain: minimal. Some trials show slight weight loss (e.g., -0.1 kg), versus olanzapine's ~+10 lbs over 10 weeks.
• Lipids and glucose: largely spared. Little of the dyslipidemia and diabetes risk that burdens olanzapine, clozapine, and quetiapine.

Other Effects

• Hyperprolactinemia: expected with potent D2 blockade (galactorrhea, amenorrhea, sexual dysfunction, and over years, bone-density concerns). Check a prolactin level if symptomatic.
• Sedation: generally less than low-potency typicals; haloperidol is relatively alerting, which is part of why it's useful in delirium-prone patients where you don't want to obtund.
• Anticholinergic effects: not from haloperidol itself, but from the benztropine/Artane you co-prescribe.

Part 6: Overdose, Toxicity, and Boxed Warnings

Boxed Warnings

Haloperidol carries one FDA boxed warning, plus a separate labeled warning for QT prolongation/torsades that is not itself boxed:

Separately, the labeled Warnings and Precautions section (added following a 2007 FDA alert on IV use) covers QT prolongation and torsades de pointes, particularly with IV administration or above recommended doses. IV haloperidol should be given with cardiac monitoring, and higher-than-labeled IV dosing is specifically cautioned against.

Acute Overdose

Overdose produces exaggerated pharmacology: severe EPS/rigidity, hypotension, sedation, and QT prolongation with arrhythmia risk. Management is supportive: airway, cardiac monitoring, correction of electrolytes, and standard arrhythmia care, with anticholinergics for the dystonic/rigid component. There is no specific antidote, and haloperidol is not usefully dialyzable (unlike lithium).

Two Toxidromes to Recognize on Sight

• NMS (see above): fever plus rigidity plus autonomic instability plus altered mentation plus high CK → stop the drug, cool, dantrolene/bromocriptine.
• Acute dystonia (oculogyric crisis, laryngospasm): frightening but rapidly reversed with IM/IV benztropine or diphenhydramine.

Part 7: Drug Interactions

Pharmacokinetic

• CYP1A2 and smoking. Haloperidol is cleared mainly by glucuronidation and CYP3A4 (with a CYP2D6 contribution); CYP1A2 is a minor pathway, but cigarette smoke induces CYP1A2 enough to matter clinically. Smokers clear haloperidol somewhat faster and run lower levels; they may need higher doses, and a patient who quits smoking (or is hospitalized on a smoke-free unit) can see levels rise, so watch for it.
• CYP inhibitors. Some SSRIs raise antipsychotic levels significantly: fluvoxamine, fluoxetine, and paroxetine can increase levels severalfold. Escitalopram (and sertraline/citalopram) are cleaner choices to pair with haloperidol when an SSRI is needed.

Pharmacodynamic

• QT-prolonging drugs: additive risk. Be cautious combining with other antipsychotics, certain antiarrhythmics, methadone, high-dose ondansetron, macrolides, and fluoroquinolones; correct K⁺/Mg²⁺.
• CNS depressants: additive sedation with benzodiazepines, opioids, alcohol.
• Anticholinergic burden: the co-prescribed benztropine/Artane stacks with other anticholinergics (antihistamines, TCAs, oxybutynin), especially dangerous in the elderly.
• Dopaminergic agents (levodopa, dopamine agonists): haloperidol antagonizes them; mutually undermining in Parkinson's disease.

Part 8: Special Populations

Pregnancy

Conventional high-potency typicals (haloperidol, fluphenazine) are among the better-studied antipsychotics in pregnancy (a legacy of decades of use, including for hyperemesis gravidarum) and carry no clearly established major teratogenic signal, in contrast to valproate or the Ebstein's-anomaly concern with lithium. The usual principle applies: avoid unnecessary medication, but weigh the very real risk of untreated psychosis or mania against a relatively reassuring fetal profile. If an antipsychotic is needed in pregnancy, haloperidol is a defensible choice. Watch the neonate for transient EPS and withdrawal signs after third-trimester exposure.

Lactation

Haloperidol is excreted into breast milk in low amounts; data are limited but it is generally considered relatively compatible with breastfeeding under monitoring. Observe the infant for sedation and any abnormal movements, and coordinate with pediatrics.

Elderly

• Boxed warning applies (increased mortality in dementia-related psychosis).
• TD risk climbs steeply with age: cumulative incidence near 25% after a year on a conventional antipsychotic, against ~5.4%/year in younger adults on haloperidol. Atypicals carry more TD risk here too, but less than haloperidol.
• Anticholinergic burden from co-prescribed benztropine is especially hazardous: confusion, falls, retention. Often better to lower the haloperidol dose than to add an anticholinergic.
• Sudden cardiac death risk is amplified by age and frailty; the ECG matters most here.
• Start low, go slow, and revisit the indication constantly.

Hepatic Impairment

Haloperidol is hepatically cleared. In moderate-to-severe hepatic impairment, reduce the dose to ≤50% of usual and titrate cautiously.

Renal Impairment

No major renal dose adjustment is established; haloperidol is not primarily renally cleared. Standard cautions apply.

Children and Adolescents

FDA-labeled for Tourette syndrome and (historically) severe behavioral problems, but pediatric use has largely ceded ground to agents with lower EPS/TD liability. Children may show withdrawal-emergent dyskinesias (often self-limiting over weeks) on discontinuation. Use conservatively and with movement monitoring.

Part 9: Discontinuation

Unlike lithium, haloperidol has no dramatic rebound-relapse withdrawal syndrome, but stopping still requires care:

• Taper, don't stop abruptly. Rapid discontinuation can precipitate rebound psychosis/agitation and can unmask or worsen tardive dyskinesia (withdrawal-emergent dyskinesia). A gradual taper is the rule, especially after long-term use.
• For the decanoate: depot levels decline slowly over weeks after the last injection, so the taper is partly built in. If you are switching agents, plan an oral bridge as decanoate levels fall.
• When TD is the reason for stopping: taper slowly (abrupt stops worsen TD), and be prepared for a transient worsening of movements before improvement.

Part 10: Haloperidol vs the Alternatives

• vs Atypical antipsychotics. Comparable efficacy for positive symptoms and mania; haloperidol wins decisively on weight, lipids, glucose, and cost, and loses decisively on EPS and TD. Age raises TD risk in both classes, and haloperidol does not close the gap: a matched comparison in older patients found significantly more TD on haloperidol than on risperidone. Much of the historical "atypicals are better" narrative rests on unfairly high haloperidol dosing.
• vs Perphenazine (Trilafon). Mid-potency perphenazine matched the atypicals in CATIE, and against haloperidol it brings fewer EPS, little weight gain, and no need for routine anticholinergic pretreatment. For many oral-antipsychotic patients, perphenazine is the better-tolerated typical, but it has no depot formulation; haloperidol decanoate wins there.
• vs Thioridazine (Mellaril). Fewer EPS than high-potency haloperidol, and inherently sedating/anticholinergic, but a 2000 FDA boxed warning for QT prolongation has made it largely obsolete.
• vs Chlorpromazine (Thorazine). More sedating, fewer EPS, but low-potency baggage (anticholinergic effects, orthostasis, more metabolic effect). Useful when sedation is the goal; inferior when you want clean potency without obtundation.
• vs Fluphenazine decanoate. The other high-potency typical LAI. Similar cost (~$15/month). Haloperidol decanoate is generally preferred for its simpler 10–15× oral-to-depot conversion (fluphenazine's ~1.2× math is fiddlier) and its once-monthly, gradual-peak kinetics.

Why is haloperidol underused? Not for lack of efficacy or evidence. It is because TD and EPS are unforgiving, the required anticholinergic co-treatment is its own burden, and the atypicals arrived with marketing budgets and a (partly overstated) tolerability story. Its rational niches are still acute agitation, acute mania as a bridge, and low-cost LAI maintenance in engaged patients.

Mechanism

Haloperidol is a potent, relatively selective D2 dopamine-receptor antagonist. Blocking D2 receptors in the mesolimbic pathway makes it an antipsychotic; blocking the same receptors elsewhere causes its liabilities. Nigrostriatal blockade produces EPS and, through chronic receptor upregulation and supersensitivity, tardive dyskinesia. Tuberoinfundibular blockade raises prolactin. It has little of the serotonergic (5-HT2A) buffering that softens striatal blockade in the atypicals, so its EPS/TD profile is steeper. At usual doses it has almost no intrinsic anticholinergic, antihistaminic, or strong alpha-adrenergic activity. That keeps sedation low and the metabolic footprint small, and hence the need for a separate anticholinergic to manage EPS. Oral half-life is ~18–24 hours, supporting once-daily dosing; the decanoate ester extends this to a monthly interval with a plasma peak around day 6.

Bedside Cheat Sheet